First Wave BioPharma Announces Initial Clinical Sites for its Phase 2 Trial of Enhanced Microgranule Delivery Formulation of Adrulipase
05 déc. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Dec. 05, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Files Investigational New Drug Application for Enhanced Microgranule Delivery Formulation of Adrulipase
30 nov. 2022 07h00 HE
|
First Wave BioPharma, Inc.
Upon IND clearance, Phase 2 clinical trial investigating adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis is expected to...
First Wave BioPharma Announces Distribution of Series F Preferred Stock to Holders of Its Common Stock
25 nov. 2022 17h45 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 25, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ: FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Closing of Private Placement
22 nov. 2022 16h15 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma, Inc. Announces Private Placement
21 nov. 2022 08h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 21, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Chairman and CEO Issues Letter to Stockholders
16 nov. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Nov. 16, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma Engages Rho to Manage Phase 2 Clinical Trial of Enhanced Adrulipase Formulation
31 oct. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 31, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma, Inc. Announces Closing of $6.0 Million Public Offering
11 oct. 2022 17h30 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 11, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...
First Wave BioPharma Presents Research Demonstrating Benefits of Improved Adrulipase Drug Delivery Formulation at AAPS 2022 PharmSci 360
10 oct. 2022 07h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 10, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc., (NASDAQ:FWBI), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in...
First Wave BioPharma, Inc. Announces Pricing of $6.0 Million Public Offering
06 oct. 2022 21h00 HE
|
First Wave BioPharma, Inc.
BOCA RATON, Fla., Oct. 06, 2022 (GLOBE NEWSWIRE) -- First Wave BioPharma, Inc. (NASDAQ:FWBI) (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the...